222 related articles for article (PubMed ID: 10735918)
1. Personal review: alarmism or legitimate concerns about long-term suppression of gastric acid secretion?
Yeomans ND; Dent J
Aliment Pharmacol Ther; 2000 Mar; 14(3):267-71. PubMed ID: 10735918
[TBL] [Abstract][Full Text] [Related]
2. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors.
Laine L; Ahnen D; McClain C; Solcia E; Walsh JH
Aliment Pharmacol Ther; 2000 Jun; 14(6):651-68. PubMed ID: 10848649
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety of proton pump inhibitors: risks of gastric neoplasia and infections.
Waldum HL; Brenna E; Sandvik AK
Expert Opin Drug Saf; 2002 May; 1(1):29-38. PubMed ID: 12904157
[TBL] [Abstract][Full Text] [Related]
4. Is there a dark side to long-term proton pump inhibitor therapy?
Nealis TB; Howden CW
Am J Ther; 2008; 15(6):536-42. PubMed ID: 19127138
[TBL] [Abstract][Full Text] [Related]
5. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study.
Sanduleanu S; Stridsberg M; Jonkers D; Hameeteman W; Biemond I; Lundqvist G; Lamers C; Stockbrügger RW
Aliment Pharmacol Ther; 1999 Feb; 13(2):145-53. PubMed ID: 10102943
[TBL] [Abstract][Full Text] [Related]
6. Marked increase in gastric acid secretory capacity after omeprazole treatment.
Waldum HL; Arnestad JS; Brenna E; Eide I; Syversen U; Sandvik AK
Gut; 1996 Nov; 39(5):649-53. PubMed ID: 9026477
[TBL] [Abstract][Full Text] [Related]
7. Considerations for long-term use of proton-pump inhibitors.
Garnett WR
Am J Health Syst Pharm; 1998 Nov; 55(21):2268-79. PubMed ID: 9825878
[TBL] [Abstract][Full Text] [Related]
8. Long-term acid control and proton pump inhibitors: interactions and safety issues in perspective.
Freston JW
Am J Gastroenterol; 1997 Apr; 92(4 Suppl):51S-55S; discussion 55S-57S. PubMed ID: 9127627
[TBL] [Abstract][Full Text] [Related]
9. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas.
Jensen RT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):4-19. PubMed ID: 16433886
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
Huang JQ; Hunt RH
Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
[TBL] [Abstract][Full Text] [Related]
11. Personal review: is profound acid inhibition safe?
Waldum HL; Brenna E
Aliment Pharmacol Ther; 2000 Jan; 14(1):15-22. PubMed ID: 10632641
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic drug interaction profiles of proton pump inhibitors.
Blume H; Donath F; Warnke A; Schug BS
Drug Saf; 2006; 29(9):769-84. PubMed ID: 16944963
[TBL] [Abstract][Full Text] [Related]
13. Review article: current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperplasia.
Robinson M
Aliment Pharmacol Ther; 1999 Oct; 13 Suppl 5():5-10. PubMed ID: 10555603
[TBL] [Abstract][Full Text] [Related]
14. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa.
Lamberts R; Brunner G; Solcia E
Digestion; 2001; 64(4):205-13. PubMed ID: 11842276
[TBL] [Abstract][Full Text] [Related]
15. Review article: the long-term use of proton-pump inhibitors.
Raghunath AS; O'Morain C; McLoughlin RC
Aliment Pharmacol Ther; 2005 Aug; 22 Suppl 1():55-63. PubMed ID: 16042660
[TBL] [Abstract][Full Text] [Related]
16. [Long-term proton pump inhibitor therapy and osteoporosis. Is there a real danger?].
Maléth J; Hegyi P
Orv Hetil; 2013 Jun; 154(26):1005-9. PubMed ID: 23800385
[TBL] [Abstract][Full Text] [Related]
17. Potential uses of intravenous proton pump inhibitors to control gastric acid secretion.
Metz DC
Digestion; 2000; 62(2-3):73-81. PubMed ID: 11025353
[TBL] [Abstract][Full Text] [Related]
18. Safety data required for proton-pump inhibitor use in children.
Scaillon M; Cadranel S
J Pediatr Gastroenterol Nutr; 2002 Aug; 35(2):113-8. PubMed ID: 12187284
[No Abstract] [Full Text] [Related]
19. Review article: proton pump inhibitors and bacterial overgrowth.
Williams C; McColl KE
Aliment Pharmacol Ther; 2006 Jan; 23(1):3-10. PubMed ID: 16393275
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome.
Hirschowitz BI; Mohnen J; Shaw S
Aliment Pharmacol Ther; 1996 Aug; 10(4):507-22. PubMed ID: 8853754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
